--------------------------------
OMB APPROVAL
--------------------------------
OMB Number: 3235-0145
Expires: December 31, 2005
Estimated average burden
hours per response ..... 11
--------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934`
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13D-1(b), (c) AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 1)*
La Jolla Pharmaceuticals
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
503459109
--------------------------------------------------------------------------------
(CUSIP Number)
January 1, 2003
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED
IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY
VALID OMB CONTROL NUMBER.
SEC 1745 (3-98)
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
J.P. Morgan Partners (BHCA), L.P. (formerly known as Chase Equity
Associates, L.P.)
13-3371826
.........................................................................
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) .....................................................................
(b) .....................................................................
--------------------------------------------------------------------------------
3. SEC Use Only ............................................................
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization Delaware
..............................
--------------------------------------------------------------------------------
5. Sole Voting Power 2,055,000
...........................
--------------------------------------------------------
Number of Shares 6. Shared Voting Power .............................
Beneficially Owned --------------------------------------------------------
by Each Reporting
Person With: 7. Sole Dispositive Power 2,055,000
........................
--------------------------------------------------------
8. Shared Dispositive Power ........................
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each
Reporting Person 2,055,000
......................
--------------------------------------------------------------------------------
10. Check if the Aggregate Amount in Row (9)
Excludes Certain Shares (See Instructions) ..........................
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9) 4.8%
................
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
--------------------------------------------------------------------------------
PN
.................................................................................
.................................................................................
.................................................................................
.................................................................................
.................................................................................
.................................................................................
--------------------------------------------------------------------------------
SEC 1745 (3-98)
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
PRELIMINARY NOTE: This Schedule 13G has been amended to reflect a change in the
controlling persons of the Reporting Person as well as a decrease in ownership
percentage as a result of an increase in outstanding shares which as a result
thereof the Reporting Person owns less than 5% of the Issuer's voting
securities.
ITEM 1.
(A) NAME OF ISSUER:
La Jolla Pharmaceuticals
(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
6455 Nancy Ridge Drive
San Diego, California 92121
ITEM 2.
(A) NAME OF PERSON FILING:
J.P. Morgan Partners (BHCA), L.P.
Supplemental information relating to the ownership and
control of the person filing this statement is included in
Exhibit 2(a) attached hereto.
(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
1221 Avenue of the Americas
New York, New York 10020
(C) CITIZENSHIP:
Delaware
(D) TITLE OF CLASS OF SECURITIES (OF ISSUER):
Common Stock, par value $0.01 per share
(E) CUSIP NUMBER:
503459109
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TOSS.SS. 240. 13D-1(B) OR 240.
13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
Not applicable.
ITEM 4. OWNERSHIP
(A) AMOUNT BENEFICIALLY OWNED:
2,055,000
(B) PERCENT OF CLASS:
4.8% (as of December 31, 2002).
(C) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
SEC 1745 (3-98)
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
(i) Sole power to vote or to direct the vote: 2,055,000
shares of Common Stock.
(ii) Shared power to vote or to direct the vote: Not
applicable.
(iii) Sole power to dispose or to direct the disposition of:
2,055,000 shares of Common Stock
(iv) Shared power to dispose or to direct the disposition of:
Not applicable.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following .
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION
(a) Not applicable.
(b) By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
SEC 1745 (3-98)
SCHEDULE 13G
ISSUER: La Jolla Pharmaceuticals CUSIP NO.: 503459109
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 13, 2003
J.P. MORGAN PARTNERS (BHCA), L.P.
By: JPMP Master Fund Manager, L.P.,
its General Partner
By: JPMP Capital Corp.,
its General Partner
By: /S/ JEFFREY C. WALKER
----------------------------------
Name: Jeffrey C. Walker
Title: President
SEC 1745 (3-98)